152 related articles for article (PubMed ID: 16624971)
1. Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease.
Aharoni R; Kayhan B; Brenner O; Domev H; Labunskay G; Arnon R
J Pharmacol Exp Ther; 2006 Jul; 318(1):68-78. PubMed ID: 16624971
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic effect of glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-inflammatory T-cells.
Aharoni R; Sonego H; Brenner O; Eilam R; Arnon R
Immunol Lett; 2007 Oct; 112(2):110-9. PubMed ID: 17719654
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effect of glatiramer acetate treatment on syndecan-1 expression in dextran sodium sulfate colitis.
Yablecovitch D; Shabat-Simon M; Aharoni R; Eilam R; Brenner O; Arnon R
J Pharmacol Exp Ther; 2011 May; 337(2):391-9. PubMed ID: 21310817
[TBL] [Abstract][Full Text] [Related]
4. R-spondin1, a novel intestinotrophic mitogen, ameliorates experimental colitis in mice.
Zhao J; de Vera J; Narushima S; Beck EX; Palencia S; Shinkawa P; Kim KA; Liu Y; Levy MD; Berg DJ; Abo A; Funk WD
Gastroenterology; 2007 Apr; 132(4):1331-43. PubMed ID: 17408649
[TBL] [Abstract][Full Text] [Related]
5. Dextran sulphate sodium induces acute colitis and alters hepatic function in hamsters.
Karlsson A; Jägervall A; Pettersson M; Andersson AK; Gillberg PG; Melgar S
Int Immunopharmacol; 2008 Jan; 8(1):20-7. PubMed ID: 18068096
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic effect of TV-5010 in a murine model of inflammatory bowel disease -- Dextran induced colitis.
Aharoni R; Brenner O; Cohen A; Arnon R
Int Immunopharmacol; 2008 Nov; 8(11):1578-88. PubMed ID: 18664394
[TBL] [Abstract][Full Text] [Related]
7. The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease.
Mencarelli A; Renga B; Palladino G; Distrutti E; Fiorucci S
Biochem Pharmacol; 2009 Nov; 78(9):1214-23. PubMed ID: 19555671
[TBL] [Abstract][Full Text] [Related]
8. Validation of murine dextran sulfate sodium-induced colitis using four therapeutic agents for human inflammatory bowel disease.
Melgar S; Karlsson L; Rehnström E; Karlsson A; Utkovic H; Jansson L; Michaëlsson E
Int Immunopharmacol; 2008 Jun; 8(6):836-44. PubMed ID: 18442787
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effect of the immunomodulator glatiramer acetate on trinitrobenzene sulfonic acid-induced experimental colitis.
Aharoni R; Kayhan B; Arnon R
Inflamm Bowel Dis; 2005 Feb; 11(2):106-15. PubMed ID: 15677903
[TBL] [Abstract][Full Text] [Related]
10. Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease.
Nakase H; Okazaki K; Tabata Y; Chiba T
J Gastroenterol; 2003 Mar; 38 Suppl 15():59-62. PubMed ID: 12698874
[TBL] [Abstract][Full Text] [Related]
11. The vagus nerve: a tonic inhibitory influence associated with inflammatory bowel disease in a murine model.
Ghia JE; Blennerhassett P; Kumar-Ondiveeran H; Verdu EF; Collins SM
Gastroenterology; 2006 Oct; 131(4):1122-30. PubMed ID: 17030182
[TBL] [Abstract][Full Text] [Related]
12. Blockade of CXCL12/CXCR4 axis ameliorates murine experimental colitis.
Mikami S; Nakase H; Yamamoto S; Takeda Y; Yoshino T; Kasahara K; Ueno S; Uza N; Oishi S; Fujii N; Nagasawa T; Chiba T
J Pharmacol Exp Ther; 2008 Nov; 327(2):383-92. PubMed ID: 18716065
[TBL] [Abstract][Full Text] [Related]
13. Reactivation of inflammatory bowel disease in a mouse model of depression.
Ghia JE; Blennerhassett P; Deng Y; Verdu EF; Khan WI; Collins SM
Gastroenterology; 2009 Jun; 136(7):2280-2288.e1-4. PubMed ID: 19272381
[TBL] [Abstract][Full Text] [Related]
14. Orally administered apple procyanidins protect against experimental inflammatory bowel disease in mice.
Yoshioka Y; Akiyama H; Nakano M; Shoji T; Kanda T; Ohtake Y; Takita T; Matsuda R; Maitani T
Int Immunopharmacol; 2008 Dec; 8(13-14):1802-7. PubMed ID: 18824249
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potency of IL2-caspase 3 targeted treatment in a murine experimental model of inflammatory bowel disease.
Shteingart S; Rapoport M; Grodzovski I; Sabag O; Lichtenstein M; Eavri R; Lorberboum-Galski H
Gut; 2009 Jun; 58(6):790-8. PubMed ID: 18978179
[TBL] [Abstract][Full Text] [Related]
16. Human thioredoxin-1 ameliorates experimental murine colitis in association with suppressed macrophage inhibitory factor production.
Tamaki H; Nakamura H; Nishio A; Nakase H; Ueno S; Uza N; Kido M; Inoue S; Mikami S; Asada M; Kiriya K; Kitamura H; Ohashi S; Fukui T; Kawasaki K; Matsuura M; Ishii Y; Okazaki K; Yodoi J; Chiba T
Gastroenterology; 2006 Oct; 131(4):1110-21. PubMed ID: 17030181
[TBL] [Abstract][Full Text] [Related]
17. The opioid antagonist naltrexone improves murine inflammatory bowel disease.
Matters GL; Harms JF; McGovern C; Fitzpatrick L; Parikh A; Nilo N; Smith JP
J Immunotoxicol; 2008 Apr; 5(2):179-87. PubMed ID: 18569389
[TBL] [Abstract][Full Text] [Related]
18. Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice.
Naito Y; Katada K; Takagi T; Tsuboi H; Isozaki Y; Handa O; Kokura S; Yoshida N; Ichikawa H; Yoshikawa T
Int J Mol Med; 2006 Jun; 17(6):997-1004. PubMed ID: 16685407
[TBL] [Abstract][Full Text] [Related]
19. Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases.
Huang TY; Chu HC; Lin YL; Lin CK; Hsieh TY; Chang WK; Chao YC; Liao CL
Toxicol Appl Pharmacol; 2009 May; 237(1):69-82. PubMed ID: 19285099
[TBL] [Abstract][Full Text] [Related]
20. A role for proteinase-activated receptor-1 in inflammatory bowel diseases.
Vergnolle N; Cellars L; Mencarelli A; Rizzo G; Swaminathan S; Beck P; Steinhoff M; Andrade-Gordon P; Bunnett NW; Hollenberg MD; Wallace JL; Cirino G; Fiorucci S
J Clin Invest; 2004 Nov; 114(10):1444-56. PubMed ID: 15545995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
